GENE AND CELL THERAPIES TARGETING CNS DISORDERS MARKET ANALYSIS

Gene and Cell Therapies Targeting CNS Disorders Market, by Therapy Type (Gene Therapy and Cell Therapy), by Indication (Alzheimer's Disease (AD), Huntington's Disease (HD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease, Multiple Sclerosis (MS), Adrenoleukodystrophy & Metachromatic Leukodystrophy, Neuropathies, and Batten Disease (BD)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Sep 2024
Code : CMI4705
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Gene and Cell Therapies Targeting CNS Disorders Market – Competitive landscape

Key players operating in the global gene and cell therapies targeting CNS disorders market include Novartis, BrainStorm Cell Therapeutics, Corestem, Q Therapeutics, Helixmith, Rapa Therapeutics, Neuroplast, StemCyte, Ferrer Internacional, Neuralstem, Ferrer Internacional, Stemedica Cell Technologies, Libella Gene Therapeutics, Sangamo Therapeutics, Hoffmann-La Roche, Longeveron, Sio Gene Therapies, Eli Lilly and Company, NeuroGeneration, Brain Neurotherapy Bio (AskBio), and UniQure Biopharma.

Gene And Cell Therapies Targeting Cns Disorders Market Report Snapshots

GENE AND CELL THERAPIES TARGETING CNS DISORDERS MARKET ANALYSIS

Leading Companies

EXISTING CLIENTELE